Graeme Fraser

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 408 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 252 citations · Full text

Principles and Recommendations for the Provision of Healthcare in Canada to Adolescent and Young Adult–Aged Cancer Patients and Survivors

Conrad V. Fernandez, Graeme Fraser, Carolyn Freeman et al. · Journal of Adolescent and Young Adult Oncology · 2011 · 117 citations · Full text

Quality Of Life, Young Adults, Adolescent Behavioral Health +25

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva et al. · Leukemia · 2018 · 116 citations · Full text

Lentivirus-mediated gene therapy for Fabry disease

Dwayne L. Barber, Ju Huang, C. Anthony Rupar et al. · Nature Communications · 2021 · 115 citations · Full text